Full history for every metric is available with a Kvantra account
Dynavax Technologies Corporation (DVAX)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 35 | 47 | 439 | 723 | 232 | 277 | 331 |
| Operating profit | $m | -4 | 10 | |||||
| Net profit | $m | -153 | -75 | 77 | 293 | -6 | 27 | -43 |
| EPS reported | $ | 0.20 | -0.37 | |||||
| Operating cashflow per share | $ | 0.51 | 0.32 | |||||
| Capex per share | $ | 0.05 | 0.06 | |||||
| FCF per share | $ | 0.46 | 0.26 | |||||
| Free cash flow | $m | 60 | 81 | |||||
| Net debt | $m | -486 | -383 | |||||
| Book value equity | $m | 597 | 534 | |||||
| Book value per share | $ | 4.48 | 3.91 | |||||
| Number of shares | m | 133.34 | 136.47 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 63.85 | - | |||||
| P/B LTM | x | 2.78 | 3.41 | |||||
| P/S LTM | x | 5.99 | 5.51 | |||||
| P/FCF LTM | x | 27.60 | 22.60 | |||||
| EV/EBITDA LTM | x | 39.81 | -56.05 | |||||
| EV/Sales LTM | x | 6.56 | 4.35 | |||||
| Earnings Yield LTM | % | 1.57% | -2.77% | |||||
| FCF Yield | % | 3.62% | 4.42% | |||||
| Quality | ||||||||
| ROE | % | 4.58% | -9.71% | |||||
| ROIC | % | -0.40% | 1.37% | |||||
| Operating margin | % | -1.49% | 4.67% | |||||
| Gross margin | % | 82.17% | 83.67% | |||||
| FCF/Sales | % | 21.70% | 11.99% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +19.36% | +26.73% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | -37.63% | +255.26% | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | 0.24 | 0.28 | |||||
| Net Debt/EBITDA | x | 3.47 | -3.40 | |||||
| EBIT/Net interest | x | -0.61 | 2.56 | |||||
| Net debt/market cap | % | -29.25% | -21.02% | |||||
| Net debt/Equity | x | -0.81 | -0.72 | |||||
| Gross debt/equity | x | 0.43 | 0.54 | |||||
Company overview
Dynavax Technologies Corporation is a biopharmaceutical firm specializing in the development and market introduction of innovative vaccines, primarily operating in the United States. The company's lead product is HEPLISAV-B, a vaccine approved for adults 18 years and older in the U.S. and Europe, which offers protection against all identified subtypes of the hepatitis B virus. Additionally, Dynavax produces and distributes CpG 1018, the specific adjuvant ingredient used in HEPLISAV-B. Dynavax maintains several strategic alliances, including a collaboration agreement with Valneva Scotland Limited, an agreement with Serum Institute of India Pvt. Ltd., and a sublicense agreement with Merck, Sharp & Dohme Corp. The company, incorporated in 1996, was originally named Double Helix Corporation before adopting the name Dynavax Technologies Corporation in September of that year. Its corporate headquarters are situated in Emeryville, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Dynavax Technologies Corporation (DVAX)
Dynavax Technologies Corporation is a biopharmaceutical firm specializing in the development and market introduction of innovative vaccines, primarily operating in the United States. The company's lead product is HEPLISAV-B, a vaccine approved for adults 18 years and older in the U.S. and Europe, which offers protection against all identified subtypes of the hepatitis B virus. Additionally, Dynavax produces and distributes CpG 1018, the specific adjuvant ingredient used in HEPLISAV-B. Dynavax maintains several strategic alliances, including a collaboration agreement with Valneva Scotland Limited, an agreement with Serum Institute of India Pvt. Ltd., and a sublicense agreement with Merck, Sharp & Dohme Corp. The company, incorporated in 1996, was originally named Double Helix Corporation before adopting the name Dynavax Technologies Corporation in September of that year. Its corporate headquarters are situated in Emeryville, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free